Cyclooxygenase (COX-2) selective inhibitors: Any better than NSAIDs?

Canadian Family Physician

Volumn 47, Issue JULY., 2001, Pages 1398-1400

  Nguyen, Anne ^a   Chaiton, Abraham ^b  

^a LIONS GATE HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME INHIBITION; GENERAL PRACTITIONER; HUMAN; METHODOLOGY; MULTICENTER STUDY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; PEPTIC ULCER; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES; SULFONES;

EID: 0034885870     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000;356:1373-4.
2. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(Suppl 56):S18-24.
3. Wolfe MM, Lichtenstein DK, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
4. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Br J Rheumatol 1998;37:937-45.
5. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies trial in osteoarthritis (SELECT). Br J Rheumatol 1998;37:946-51.